[Experience in treating portal thromboses in patients with chronic myeloproliferative diseases].
Ter Arkh
; 88(1): 89-95, 2016.
Article
in Ru
| MEDLINE
| ID: mdl-26978616
ABSTRACT
Patients with myeloproliferative diseases (MPD) are noted to be at high risk for portal thromboses. This problem gives rise to disability if it is untimely treated or resistant to therapy. The paper gives the experience of the Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation, in using antithrombin III in MPD patients (3 patients with primary myelofibrosis, 3 with essential thrombocythemia) and acute and subacute portal vein thromboses resistant to therapy with direct anticoagulants. In all 5 cases, the use of antithrombin III in combination with low-molecular-weight heparin showed a positive clinical effect as rapid relief of pain syndrome and comparatively early (3-week to 1.5-2-month) recanalization of thrombosed vessels. Three clinical cases are described in detail.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antithrombin III
/
Heparin, Low-Molecular-Weight
/
Primary Myelofibrosis
/
Thrombocythemia, Essential
/
Budd-Chiari Syndrome
Type of study:
Diagnostic_studies
/
Etiology_studies
Limits:
Adult
/
Female
/
Humans
Language:
Ru
Journal:
Ter Arkh
Year:
2016
Document type:
Article
Affiliation country:
RUSSIA